pharmazz

Developing products that are first-in-class with unique mechanism of action and are different from those of existing therapies

about

Pharmazz, Inc.

Pharmazz, Inc. is a clinical stage pharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target critical care medicine. The company is developing several clinical-stage product candidates, PMZ-2010, PMZ-1620 and PMZ-2123 for which it holds global marketing rights.

Established in 2010, Pharmazz, Inc. is an emerging global pharmaceutical company. Focus of the company is to discover, acquire, develop and market novel pharmaceutical products for use in critical care and hospital settings.

Product Pipeline

Product
Pre-Clinical
Clinical

phase 1

phase 2

phase 3

Market

Hypovolemic Shock (PMZ-2010)

Ischemic stroke (PMZ-1620)

Alzheimer's Disease (PMZ-1620)

Spinal Cord Injury (PMZ-1620)

Cardiac Arrest (PMZ-2010)

Opioid Tolerance (PMZ-2123)

Diabetic Ketoacidosis (PMZ-2123)

Post-Operative Pain (PMZ-2010)

Products

Hypovolemic Shock

Hypovolemic Shock

Ischemic Stroke

Ischemic Stroke

Alzheimer's Disease

Alzheimer's Disease

Spinal Cord Injury

Spinal Cord Injury

Cardiac Arrest

Cardiac Arrest

Opioid Tolerance

Opioid Tolerance

Diabetic Ketoacidosis

Diabetic Ketoacidosis

Postoperative Pain

Postoperative Pain

phase 1